Alzheimer's Association International Conference (AAIC)

The $100 million PROTECT-Cog trial will test whether adding a GLP-1 drug to the proven U.S. POINTER lifestyle intervention further cuts dementia risk in at-risk older adults.

PrevenTRON, a study of trontinemab, will enroll 1600 cognitively unimpaired participants identified by elevated plasma p-tau217, using time to clinical progression as the primary endpoint.

SAR448851 showed favorable safety, high CNS penetration, and up to 50% reductions in CSF soluble TREM2 in phase 1, supporting the design of TREMHANCE, a phase 2 trial now in final planning with p-tau217 as its primary endpoint.

The global phase 3 registration trial enrolled 1535 patients across 240 sites and has completed its 52-week double-blind treatment phase, with no unexpected safety signals observed, even in participants on concomitant antiamyloid therapies.

Across 3 first-in-human studies in healthy volunteers and cognitively impaired adults, MK-2214 demonstrated dose-proportional pharmacokinetics, an approximately 80-day half-life, and near-complete suppression of free pS413 tau in CSF at doses of 20 mg and above.

The assistant professor in the Department of Behavioral Science at the University of Kentucky discusses a nonpharmacologic intervention designed to address sensory processing impairments in older adults with dementia. [WATCH TIME: 5 minutes]

At AAIC 2026, the senior research professor of neurology at Indiana University School of Medicine discussed the evolving role of blood-based Alzheimer disease biomarkers, particularly p-tau217.

At AAIC 2026, professor of neurology at Washington University in St. Louis discussed how integrating clinical assessment with amyloid biomarkers can improve diagnostic accuracy in Alzheimer disease. [WATCH TIME: 5 minutes]

The 60 mg dose showed the largest treatment effect, slowing decline by 26% on CDR-SB, 42% on ADAS-Cog13, and 50% on MMSE at 18 months, while all doses produced 50% to 65% reductions in CSF total tau and unprecedented tau PET reductions across brain regions.

At AAIC 2026, associate professor of neurology at Albert Einstein College of Medicine discussed a culinary medicine intervention to improve MIND diet adherence and mood in older adults with type 2 diabetes. [WATCH TIME: 5 minutes]

MCLENA-1 enrolled only 6 completers due to funding constraints but demonstrated 12 months of continuous lenalidomide was safe and tolerable, with nonsignificant trends favoring treatment on cognition and global outcomes.

A new phase 2 trial, presented at AAIC 2026, aims to evaluate the effects of urolithin A on mitophagy/autophagy activity, oxidative stress, multi-omic profiling, and cognitive function in APOE4 carriers.

The APPLAUDS trial will evaluate mivelsiran, an intrathecally delivered siRNA targeting amyloid precursor protein, in cognitively stable adults aged 40 to 55 with early-stage Down syndrome and early-stage Alzheimer disease who have elevated amyloid burden.

In the largest study of its kind, researchers examined the potential neurological effects of repetitive head impacts in retired elite soccer players, with findings offering new insights into symptoms, brain structure, and future research directions. [WATCH TIME: 3 Minutes]

Post hoc analyses from the phase 3 GRADUATE program suggest higher baseline tau pathology may limit amyloid removal with gantenerumab, offering new insight into factors that could influence response to anti-amyloid therapy.

In a prespecified analysis presented at AAIC 2026, findings showed that plasma p-tau217 declined from baseline in valiltramiprosate-treated MCI patients compared with placebo over 78 weeks.

Ahead of the 2026 Alzheimer's Association International Conference, David Wolk, MD, discusses the meeting's biggest scientific themes, from plasma biomarkers and disease-modifying therapies to emerging technologies and evolving clinical practice.

The vice president of scientific engagement at the Alzheimer’s Association provided clinical insights on the most major considerations and precautions clinicians should have about diagnostic and commercially available tests for suspected Alzheimer disease. [WATCH TIME: 3 minutes]

In this seventh episode, Cohen outlined emerging Alzheimer therapies targeting amyloid, tau, and inflammation, highlighting novel antibody approaches, genetic knockdown strategies, and repurposed GLP-1 receptor agonists. Supported by Eli Lilly.

In this sixth episode, Cohen discussed aligning patient expectations with the goals of antiamyloid antibody treatment, emphasizing disease slowing, eligibility factors, and real-world satisfaction data. Supported by Eli Lilly.

The vice president of scientific engagement at the Alzheimer's Association shared data presented at AAIC 2025 from the phase 3 U.S. POINTER study among patients at risk for dementia. [WATCH TIME: 4 minutes]

In this fifth episode, Cohen explained the types, risks, and monitoring protocols for ARIA with antiamyloid antibodies, emphasizing MRI schedules, symptom vigilance, and individualized patient safety considerations. Supported by Eli Lilly.

In this fourth episode, Sharon Cohen, MD, FRCPC, talked about key differences between lecanemab and donanemab in terms of eligibility requirements to the receive the treatment. Supported by Eli Lilly.

The vice president of scientific engagement at the Alzheimer's Association discussed new data on amyloid-targeting therapies, expanded diagnostic tools, and emerging clinical guidelines for Alzheimer disease presented at AAIC 2025. [WATCH TIME: 5 minutes]

At AAIC 2025, the associate professor in the Department of Psychiatry at McGill University talked about the strengths and limitations of PET and blood biomarkers for Alzheimer disease. [WATCH TIME: 5 minutes]

The chief scientific officer at Alzheon talked about a symposium on the role of amyloid-beta oligomers in AD and phase 3 clinical data of valiltramiprosate presented at AAIC 2025. [WATCH TIME: 5 minutes]

At AAIC 2025, the founder and CEO at Veravas discussed the company’s VeraBIND tau pathology blood test, highlighting its potential to detect Alzheimer disease earlier with high accuracy. [WATCH TIME: 4 minutes]

At AAIC 2025, the chief executive officer at ALZpath discussed the growing adoption of the company’s pTau217 antibody blood test for AD research, emphasizing its potential role in early detection. [WATCH TIME: 4 minutes]

The principal scientist of neuroscience discovery at Merck presented preclinical data at AAIC 2025 supporting the development of MK-2214, an anti-tau antibody designed to slow or prevent the progression of AD. [WATCH TIME: 5 minutes]

At AAIC 2025, Alberto Ramos, MD, FAAN, director of the sleep disorders program at the University of Miami, discussed the association between long sleep duration, specific sleep phenotypes, and progressive cognitive decline in Hispanic populations.